SCHEMBL733028

SCHEMBL733028

[c]1ccc2c(-c3ccccc3)noc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.40
ESR2 Q92731 5/20 0.40
PTGS1 P23219 2/20 0.40
PTGS2 P35354 2/20 0.40
HTR7 P34969 1/20 0.38
PLK1 P53350 1/20 0.38
NR4A2 P43354 1/20 0.38
NPC1 O15118 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730985 0.86 ESR1 (0.40) ESR1ESR2PTGS1PTGS2HTR7
SCHEMBL2420862 0.78 ESR1 (0.45) ESR1ESR2LMNAEPHX2
SCHEMBL541948 0.77 ESR1 (0.55) ESR1ESR2PTGS1PTGS2PLK1
Methylamine SCHEMBL27463475 0.73 ESR1 (0.50) ESR1ESR2PTGS1PTGS2PLK1
Methylamine SCHEMBL27489583 0.71 ESR1 (0.49) ESR1ESR2PTGS1PTGS2PLK1
Methylamine SCHEMBL28743725 0.71 ESR1 (0.49) ESR1ESR2PTGS1PTGS2PLK1
SCHEMBL28430363 0.71 ESR1 (0.56) ESR1ESR2LMNAEPHX2
SCHEMBL479144 0.71 IDO1 (0.35)
SCHEMBL15091080 0.71 CHRNB2 (0.36)
SCHEMBL6843721 0.70 HIF1A (0.38) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 ESR1 1044/4885ESR2 708/4885PTGS1 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.